Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Donepezil · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | 5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days) |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Donepezil | DRUG | 5 mg capsule, orally, once daily, first 14 days of treatment |
| Placebo to match Aricept | DRUG | Placebo capsule, orally, 84 days of treatment |
Inclusion Criteria: * Clinical diagnosis of probable AD according to NINCDS-ADRDA criteria. * The patient should live with an appropriate caregiver at home, or in a community dwelling. A caregiver should be capable of accompanying the patient to clinic visits or attending study visits in the patien...
Top 20 of 24 competitors
Donepezil is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is currently in early Phase 1 clinical development, with one completed trial evaluating its effects on cognitive function after 12 weeks of treatment.
Donepezil is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical research to evaluate the drug's potential in treating Alzheimer's Disease.
Donepezil is in early Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One early Phase 1 trial has been completed, and the drug remains under clinical investigation for Alzheimer's Disease.
Donepezil has one completed clinical trial registered under NCT01024660, titled 'The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil.' This early Phase 1 study enrolled 155 participants with Alzheimer's Disease across Canada, Peru, Poland, and South Africa.
Donepezil is the generic name for the medication also known as Aricept. The drug is being studied by AstraZeneca for Alzheimer's Disease, and the completed clinical trial NCT01024660 evaluated its effects on cognitive function in patients with this condition.